

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LANSEN PHARMACEUTICAL HOLDINGS LIMITED

朗生醫藥控股有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 503)

**CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR,
MEMBER OF THE AUDIT COMMITTEE
AND MEMBER OF THE REMUNERATION COMMITTEE**

**RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR, MEMBER OF
THE AUDIT COMMITTEE AND MEMBER OF THE REMUNERATION
COMMITTEE**

The board of directors (the “**Board**”) of Lansen Pharmaceutical Holdings Limited (the “**Company**”) hereby announces that Mr. Fritz Heinrich Horlacher (“**Mr. Horlacher**”) has resigned as an Independent Non-executive Director, a member of the Audit Committee and a member of the Remuneration Committee of the Company with effect from 10 February 2022 upon the expiry of current appointment due to his desire to devote more time to his other personal commitments over 10 years of service in the Company.

Mr. Horlacher has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company.

The Chairman and the Board express their sincere gratitude to Mr. Horlacher for his service and valuable contribution made to the Company.

**APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND
MEMBER OF THE AUDIT COMMITTEE**

The Company is pleased to announce that Ms. Chan Ching Har, Eliza (“**Ms. Chan**”) has been appointed as an Independent Non-executive Director and a member of the Audit Committee of the Company with effect from 10 February 2022.

Ms. Chan, SBS, JP, LL.D. (Hon), holds the qualifications of Barrister & Solicitor of British Columbia Supreme Court, Canada, Solicitor of the Supreme Court of England and Wales and Solicitor of the High Court of Hong Kong. Ms. Chan is a member of the National Committee of the Chinese People's Political Consultative Conference ("CPPCC"), a standing member of the CPPCC Tianjin Committee, Foreign Economic Affairs Legal Counsel to the Tianjin Municipal People's Government, an arbitrator of China International Economic and Trade and Arbitration Commission (CIETAC).

Ms. Chan previously served as a member of the Selection Committee for the selection of the First Chief Executive of Hong Kong SAR, and member of the Election Committee for the selections of the Chief Executive of Hong Kong SAR and the Hong Kong SAR delegates to the National People's Congress. She was Chairman of Hong Kong CPPCC (Provincial) Members Association and now serves as Permanent Honorary Chairman. She is Vice-President of Hong Kong Friendship Association and Honorary President of Hong Kong China Chamber of Commerce. Ms. Chan also served at a number of Hong Kong Government appointed positions, notably as a member of the Hong Kong Hospital Authority, member of Hong Kong Public Service Commission, member of the Hong Kong Board of Education, member of Hong Kong Examinations and Assessment Authority, Chairman of Public Complaints Committee under Hong Kong Hospital Authority, Chairman of Kowloon Hospital, Chairman of Hong Kong Eye Hospital, Chairman of Tseung Kwan O Hospital, member of the Governing Committee of Queen Elizabeth Hospital, member of the Medical Council of Hong Kong, Chairman of Pensions Appeal Panel, member of Administration Appeals Board, adjudicator of Hong Kong Immigration Tribunal, member of Disciplinary Panel of Institute of Accountants, Council member of The University of Science & Technology and Board member of Hong Kong Science and Technology Park Corporation.

Ms. Chan is senior consultant of Yang Chan & Jamison LLP and senior advisor of Deloitte Touche Tohmatsu. She was a former independent non-executive director of Cathay International Holdings Limited, an ultimate holding company of the Company, and a former non-executive director of Tianjin Development Holdings Limited (stock code: 882). She is currently an independent non-executive director of Bank of Communications (HK) Limited, China Electronics Optics Valley Union Holding Company Limited (stock code: 798) and Tong Ren Tang Technologies Co., Ltd. (stock code: 1666).

Pursuant to the letter of appointment entered into between the Company and Ms. Chan, the appointment of Ms. Chan is for a term of three years commencing from 10 February 2022.

The amount of director's fee of Ms. Chan is HK\$275,000 per annum. The letter of appointment is subject to the Articles of Association of the Company and the Listing Rules of the Stock Exchange which contains provisions for early retirement and retirement by rotation of directors. The emoluments of the independent non-executive directors of the Company are determined by reference to the remuneration benchmark in the industry and the prevailing market conditions.

As at the date of this announcement, Ms. Chan (i) does not have any relationship with any Directors, chief executive, senior management, significant or substantial or controlling shareholders of the Company; (ii) does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Future Ordinance; and (iii) save as disclosed above, did not hold any other directorships in the last three years up to the date of this announcement in public companies, the securities of which are listed on any securities market in Hong Kong or overseas.

Save as disclosed above, there is no information in relation to the appointment of Ms. Chan which is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and there is no other matters that needs to be brought to the attention of the shareholders of the Company.

The Board would like to extend its warmest welcome to Ms. Chan to join the Board.

By order of the Board
Lansen Pharmaceutical Holdings Limited
Wu Zhen Tao
Chairman

Hong Kong, 10 February 2022

As at the date of this announcement, the executive managing Director is Mr. Chen Li; the non-executive Directors are Mr. Wu Zhen Tao, Mr. Stephen Burnau Hunt and Ms. Liu Xuezi; the independent non-executive Directors are Mr. Chan Kee Huen, Michael, Mr. Yeung Tak Bun, Allen and Ms. Chan Ching Har Eliza.